Just saw that Rachelle Jacques took over as chair at Corbus Pharma back in May 2025. Interesting move because she's got like 25+ years in the biotech space, so not exactly a random pick. She was already on their board for six years before this, so the company basically promoted someone who already knew what was going on.

What caught my attention is the timing - Rachelle Jacques stepped in right when they had all three pipeline drugs supposed to hit clinical readouts in the second half of last year. Their oncology programs (CRB-701 and CRB-601) are targeting some pretty aggressive cancers, and they've also got an obesity drug in the mix. Pretty solid portfolio if the data comes through.

The previous chair Alan Holmer stayed on the board, so it's not like they completely cleaned house. Rachelle Jacques actually has a solid track record - she was CEO at Enzyvant before and got RETHYMIC approved under that new regenerative medicine pathway, which is no joke. Also had exec roles at bigger pharma like Alexion.

Insider trading was interesting though - saw the CEO, CMO, and CFO all selling shares around that time. Not a huge amount, but worth noting. Hedge funds were pretty mixed too, some adding positions, others bailing out. Classic biotech volatility I guess - everyone waiting to see if the clinical data actually delivers.